Sanofi says that it is not pursuing its mRNA vaccineBloombergSanofi does not plan to pursue the development of a messenger RNA (mRNA) vaccine against COVID-19 because the shot will come too late to market. “Sanofi is focusing therefore on a recombinant protein candidate to address the needs of a booster vaccine.”A test tube is pictured in front of a Sanofi logo on Sept. 8. Ordinarily a giant in the vaccines space, Sanofi has lagged behind BioNTech SE and Moderna Inc in the pandemic as they raced ahead with mRNA shots that have now been injected into arms more than 1 billion times and generated billions in revenue. Last month, Sanofi bought its mRNA development partner Translate Bio Inc for US$3.2 billion with the aim of moving beyond vaccines and harnessing mRNA for treatments — something that BioNTech is investigating for cancer. “Our goal is to unlock the potential of mRNA in other strategic areas such as immunology, oncology and rare diseases in addition to vaccines,” Sanofi chief executive officer Paul Hudson said at the time of the deal.

Source: Taipei Times September 28, 2021 07:30 UTC